亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

医学 多发性骨髓瘤 抗体 耐火材料(行星科学) 肿瘤科 内科学 双特异性抗体 癌症研究 免疫学 生物 单克隆抗体 天体生物学
作者
Ajai Chari,Cyrille Touzeau,Carolina Schinke,Monique C. Minnema,Jesus G. Berdeja,Albert Oriol,N. W. van de Donk,Paula Rodriguez Otero,Elham Askari,Maria-Victoria Mateos,Luciano J. Costa,Jo Caers,Leo Rasche,Amrita Krishnan,Deeksha Vishwamitra,Xuewen Ma,Xiang Qin,Katharine S. Gries,Michela Campagna,Tara Masterson,Brandi Hilder,Jaszianne Tolbert,Thomas Renaud,Jenna D. Goldberg,Christoph Heuck,Jesus F. San-Miguel,Philippe Moreau
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 384-387 被引量:18
标识
DOI:10.1182/blood-2022-159707
摘要

Introduction: G protein-coupled receptor family C group 5 member D (GPRC5D) has limited expression in normal human tissue but is highly expressed on malignant plasma cells, making it a promising immunotherapy target for patients (pts) with multiple myeloma (MM). Talquetamab is a first-in-class, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D and CD3 receptors. MonumenTAL-1 is a phase 1/2 trial (NCT03399799/NCT04634552) of talquetamab in pts with RRMM. In phase 1 of MonumenTAL-1, collective safety, efficacy, pharmacokinetic (PK), and pharmacodynamic (PD) data supported selection of 2 recommended phase 2 doses (RP2Ds) for talquetamab: 0.405 mg/kg subcutaneous (SC) weekly (QW) and 0.8 mg/kg SC every other week (Q2W). Here, we report results for pts treated at these RP2Ds in phase 1 and 2 of MonumenTAL-1. Methods: Eligible pts in phase 1 had measurable MM and had progressed on or were intolerant to standard therapies. Pts in phase 2 had received ≥3 prior lines of therapy (LOT), including ≥1 proteasome inhibitor, ≥1 immunomodulatory drug, and ≥1 anti-CD38 monoclonal antibody (ie, triple-class exposed). In phase 1, 0.405 mg/kg SC QW was a putative RP2D; this was modified to 0.4 mg/kg SC QW in phase 2 for convenience. Phase 1 and 2 data were combined for analysis. Step-up dosing was used to mitigate risk of severe cytokine release syndrome (CRS). Primary endpoint of phase 2 was overall response rate (ORR) per IMWG criteria based on independent committee review. Key secondary endpoints were duration of response (DOR), rate of very good partial response or better (≥VGPR), rate of complete response or better (≥CR), time to response, progression-free survival (PFS), and incidence of AEs. AEs were graded by CTCAE v4.03; CRS events were graded per ASTCT criteria. PD parameters were measured at baseline and through day 1 of cycle 2. Results: As of May 16, 2022, 288 pts with no prior exposure to T-cell redirecting therapies had received talquetamab at the RP2Ds in phase 1 or 2. In 143 pts treated at 0.4 mg/kg QW (median time since diagnosis: 6.7 years), median age was 67 years (range 46-86), pts received a median of 5 prior LOT (range 2-13), 31.1% had high-risk cytogenetics, 23% had extramedullary disease, 19.6% had ISS stage 3 disease, 100%/74% were triple-class exposed/refractory, and 73%/29% were penta-drug exposed/refractory; median follow-up was 11.0 months (range 0.5+-26.1). Baseline characteristics were similar among 145 pts who received 0.8 mg/kg Q2W (median follow-up: 5.1 months [range 0.2+-17.9]). In 143 pts treated at 0.4 mg/kg QW, ORR was 73% (≥VGPR: 58%; ≥CR: 29%). Responses were durable and deepened over time (Figure). Median time to response was 1.2 months (range 0.2-5.0). Median time to CR was 2.1 months (range 1.1-12.4). Median DOR was 9.3 months (95% CI, 6.6-20.2; range 1-23+). Median PFS was 7.5 months (95% CI, 5.7-9.2 [38% censored]). ORRs in pts who were triple-class refractory (72% [76/106]) and penta-drug refractory (71% [30/42]) were comparable to the overall population. Efficacy at 0.8 mg/kg Q2W will be presented at the meeting. The most common AEs at 0.4 mg/kg QW/0.8 mg/kg Q2W were CRS (79%/72%; grade 3: 2%/1%; grade 4: 0%/0%), dysgeusia (48%/46%; grade 3/4: not applicable [NA]), and anemia (45%/39%; grade 3: 31%/25%; grade 4: 0%/0%]); skin-related AEs occurred in 56%/68% (grade 3: 0%/1%; grade 4: NA) and nail disorders in 52%/43% (grade 3: 0%/0%; grade 4: NA) of patients. Cytopenias, including neutropenia in 34%/28% (grade 3: 20%/17%; grade 4: 10%/6%) and thrombocytopenia in 27%/27% (grade 3: 10%/8%; grade 4: 10%/8%), were generally limited to the first few cycles. At 0.4 mg/kg QW/0.8 mg/kg Q2W, infections occurred in 57%/50% of pts (grade ≥3: 19%/13%); 4.9%/6.2% discontinued, 8.4%/13.8% had dose delays, and 14.7%/6.2% had dose reductions due to AEs. There were 2 deaths due to COVID-19 (1 patient at each RP2D). Talquetamab exposure was comparable at the two RP2Ds. No clinically significant effect of anti-talquetamab antibodies on PK, efficacy, or AEs was observed. PD changes were comparable at both RP2Ds and consistent with talquetamab activity, including T-cell activation, redistribution, and induction of cytokines. Conclusions: Talquetamab demonstrated robust efficacy and manageable safety in pts with heavily pretreated RRMM. Additional phase 1 studies (NCT04586426; NCT04108195; NCT05050097) are evaluating talquetamab in combination with other agents in pts with RRMM. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
魔幻雅柔完成签到,获得积分10
1秒前
月亮打烊完成签到 ,获得积分10
4秒前
文静楷瑞完成签到,获得积分10
7秒前
fx完成签到 ,获得积分10
9秒前
9秒前
fantasy的应助被十三采纳,获得10
10秒前
深情安青的应助被outlast采纳,获得10
15秒前
十三完成签到,获得积分10
16秒前
17秒前
21秒前
拼搏问薇完成签到 ,获得积分10
22秒前
23秒前
Abcqqq完成签到 ,获得积分10
23秒前
海洋球完成签到,获得积分10
25秒前
ll完成签到,获得积分20
25秒前
小蘑菇的应助被xx2026采纳,获得10
26秒前
27秒前
kxz完成签到 ,获得积分10
27秒前
28秒前
gale发布了新的文献求助10
31秒前
红墨发布了新的文献求助30
32秒前
34秒前
怕黑的驳完成签到,获得积分10
35秒前
37秒前
38秒前
39秒前
40秒前
吐司发布了新的文献求助10
41秒前
冷静新烟完成签到,获得积分10
41秒前
gale完成签到,获得积分10
44秒前
49秒前
49秒前
TIDUS完成签到,获得积分10
51秒前
独特的念柏完成签到,获得积分10
55秒前
sadascaqwqw发布了新的文献求助10
55秒前
36hours完成签到,获得积分10
56秒前
田様的应助被冷静新烟采纳,获得10
56秒前
57秒前
Ava的应助被典雅的可乐采纳,获得10
1分钟前
赘婿的应助被胡图图不糊涂采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541